Lanreotide shortage — NZ supply status & alternatives

Lanreotide

—

🇦🇺 AUST R 371880 · Amdipharm Mercury Australia Pty Ltd

In supply · Australia

Mytolac

In supply · 🇦🇺 Australia · short in🇺🇸 US🇮🇹 IT🇳🇿 NZ🇳🇱 NL

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$849.73details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Lanreotide
Brand names	Mytolac
Therapeutic category	Auto-created by Pharmac — New Zealand Medicine Supply Disruptions scraper
Controlled substance	No
Marketing-authorisation holders	Amdipharm Mercury Australia Pty Ltd, Generics (UK) Limited, SUN PHARMA UK LIMITED, ZENTIVA PHARMA UK LIMITED +4 more
Registrations on file	24
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$849.73

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

lanreotide 60 mg/0.5 mL injection, 0.5 mL syringe

Source: PBSEffective July 2026 · AUD

Other markets

🇮🇹 IT

€1673.82

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

12 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Bachem Americas INCAlp Pharm Beijing CO LTDSinopep-Allsino Biopharmaceutical CO LTDSun Pharmaceutical Industries LTDBcn Peptides SASichuan Frontier Biopharmaceutical CO LTD+6 more

Manufacturing countries: United States, China, India, Spain · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇳🇿

New Zealand

Pharmac · 4d ago

High

🇺🇸

United States

FDA MedWatch · 1mo ago

High

🇳🇱

Netherlands

CBG-MEB · 1d ago

Medium

🇮🇹

Italy

AIFA · 1d ago

Medium

Verified timeline regulator events

🇳🇿 19 Mar 2026

high reported

🇺🇸 13 Mar 2026

high reported

🇳🇱 5 Mar 2026

medium reported

🇺🇸 2 Jan 2026

high reported

🇮🇹 29 Nov 2023

medium reported

🇮🇹 28 Sept 2023

medium reported

Sources official regulators

🇳🇱

CBG-MEB

verified 1d ago

verify ↗

🇮🇹

AIFA

verified 1d ago

verify ↗

🇳🇿

Pharmac

verified 4d ago

verify ↗

🇺🇸

FDA MedWatch

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders24 registrations · 8 MA holders

Product	Strength	Form	Market	MA holder	Status
MYTOLAC lanreotide	90 mg	—	🇦🇺 AU	Amdipharm Mercury Australia Pty Ltd	Active
MYTOLAC lanreotide	120 mg	—	🇦🇺 AU	Amdipharm Mercury Australia Pty Ltd	Active
MYTOLAC lanreotide	60 mg	—	🇦🇺 AU	Amdipharm Mercury Australia Pty Ltd	Active
Lanreotide Mylan	60 MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
Lanreotide Mylan	90 MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
Lanreotide Mylan	120 MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
Lanreotide Sun	60 MG	injection	🇬🇧 GB	SUN PHARMA UK LIMITED	Active
Lanreotide Sun	90 MG	injection	🇬🇧 GB	SUN PHARMA UK LIMITED	Active
Lanreotide Sun	120 MG	injection	🇬🇧 GB	SUN PHARMA UK LIMITED	Active
Lanreotide Zentiva	60 MG	injection	🇬🇧 GB	ZENTIVA PHARMA UK LIMITED	Active
Lanreotide Zentiva	90 MG	injection	🇬🇧 GB	ZENTIVA PHARMA UK LIMITED	Active
Lanreotide Zentiva	120 MG	injection	🇬🇧 GB	ZENTIVA PHARMA UK LIMITED	Active
Lanreotide Ipsen	60 MG	injection	🇬🇧 GB	IPSEN LIMITED	Active
Lanreotide Ipsen	90 MG	injection	🇬🇧 GB	IPSEN LIMITED	Active
Lanreotide Ipsen	120 MG	injection	🇬🇧 GB	IPSEN LIMITED	Active

+9 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.